1. Curriculum Vitae
Mao-Bin Meng, M.D., Ph.D.
Office Address:
Department of Radiation Oncology and CyberKnife Center
Key Laboratory of Cancer Prevention and Therapy
Tianjin Medical University Cancer Institute & Hospital
National Clinical Research Center for Cancer
Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District
Tianjin 300060, P.R. China
Phone: +86-22-23341405
FAX: +86-22-23341405
E-mail: doctormm991@hotmail.com
Faculty Appointments:
12/20/2014- Associate Professor, Department of Radiation
Oncology, Tianjin Medical University Cancer
Institute & Hospital
07/01/2011-12/29/2014 Assistant Professor, Department of Radiation
Oncology, Tianjin Medical University Cancer
Institute & Hospital
Hospital Appointments:
07/01/2011- Attending Radiation Oncologist, Tianjin Medical
University Cancer Institute & Hospital
07/01/2008-06/30/2011 Attending Radiation Oncologist, West China
Hospital, West China School of Medicine,
Sichuan University
07/01/2005-06/30/2008 Attending Physician, West China Hospital, West
China School of Medicine, Sichuan University
Education and Postgraduate Training:
07/01/2011-12/20/2014 Residency, Radiation Oncology, Tianjin Medical

2. University Cancer Institute & Hospital
01/07/2011-01/09/2008 Ph.D. in Radiation Biology, West China Hospital,
West China School of Medicine, Sichuan
University
01/07/2008-01/09/2005 Doctorate in Internal Medicine and M.S. in
Clinical Pharmacology, West China Hospital,
West China School of Medicine, Sichuan
University
Research founding:
Function and mechanism of mesenchymal stem cell in microvasculature injured
repair induced by hypofractionated radiotherapy
PI: (Mao-Bin Meng) 1/1/2013-12/30/2015
NSFC 81201754 RMB230, 000
The molecular mechanism of mesenchymal stem cell in microvasculature injured
repair induced by hypofractionated radiotherapy in NSCLC
PI: (Mao-Bin Meng) 1/1/2013-12/30/2015
20121202120014 RMB40, 000
Role and mechanism of RIP1/RIP3 in regulating cancer cell necroptosis in
hypofractionated radiotherapy
Co-PI: (Zhi-Yong Yuan and Mao-Bin Meng) 1/1/2015-12/30/2018
NSFC 81472797 RMB720, 000
Hypofractionated radiotherapy induced cancer cell necroptosis in NSCLC
Co-PI: (Zhi-Yong Yuan and Mao-Bin Meng) 1/1/2015-12/30/2018
NSFC 81472797 RMB300, 000
The mechanism of histone acetylation modification in the pathogenesis of the ITP
Co-PI: (Hai-Feng Zhao and Mao-Bin Meng) 1/1/2015-12/30/2018
NSFC 81470283 RMB700, 000
The molecular mechanism study on halofuginone reversing
epithelial-mesenchymal transition of lung cancer cells caused by radiotherapy
PI: (Lu-Jun Zhao) 1/1/2014-12/30/2017

3. NSFC 81372429 RMB700, 000
The regulatory mechanisms of the biological effects of NSLC microvasculature
after hypofractionated radiotherapy
PI: (You Lu) 1/1/2012-12/30/2015
NSFC 81172131 RMB600, 000
SIRT1 inducing DNA repair and promoting autophagy to alleviate the
radiation-induced lung injury
PI: (Jian-Xin Xue) 1/1/2012-12/30/2014
NSFC 81101693 RMB220, 000
Invited Lectures:
2013. Invited speaker at the 4th
Asia-Pacific Primary liver cancer expert meeting
2013. Invited speaker at the 10th
Chinese Radiation Oncology and SANTRO
meeting
2013. Invited speaker at the forum of individualized radiotherapy medicine
2014. Poster at the 25th
ASTRO meeting
2014. Invited speaker at the forum of individualized radiotherapy medicine
2014. Invited speaker at the 1th
CyberKnife training meeting
2015. Invited speaker at the 2th
CyberKnife training meeting
Peer reviewer:
Cancer Research
International Journal of Radiation Oncology Biology Physics
Radiotherapy and Oncology
Oncotarget
PloS One
Cancer Letters
OncoTagets and Therapy
Radiation Research
Radiation Oncology
BMC Cancer
Medical Oncology

4. Journal of alternative and complement medicine
Journal of Thoracic Disease
Cancer Science
Editorial Advisory Board:
Journal of Thoracic Disease (SCIE), 2012-Present
World Journal of Clinical Oncology (Medline) 2014-present
Bibliography:
1. Meng MB, Wang HH, Cui YL, Lan J, Wu ZQ, Zeng XL, Guo WH, Zhao LJ,
Yuan ZY, Wang P. Mesenchymal stem cells generate pericytes to promote tumor
recurrence via vasculogenesis after stereotactic body radiation therapy. Stem Cells
2015, Submitted (IF: 7.90).
2. Meng MB, Wang HH, Zaorsky NG, Zhao XZ, Wu ZQ, Jiang B, Song YC,
Zhuang HQ, Li FT, Zhao LJ, Wang CL, Li K, Wang P, Yuan ZY. Clinical
evaluation stereotactic radiation therapy for recurrent or second primary
mediastinal lymph node metastases originating from non-small cell lung cancer.
Oncotarget 2015; In Press (IF: 6.63)
3. Meng MB, Jiang XD, Deng L, Na FF, He JZ, Xue JX, Guo WH, Wen QL, Mo
XM, Lang JY, Lu Y. Enhanced radioresponse with a novel recombinant human
endostatin via tumor vasculature remodeling: experimental and clinical evidence.
Radiother Oncol 2013; 106: 130-137. (IF: 5.58)
4. Meng MB, Zaorsky NG, Jiang C, Tian LJ, Wang HH, Liu CL, Wang J, Tao Z,
Sun Y, Wang J, Pang QS, Zhao LJ, Yuan ZY, and Wang P. Radiotherapy and
chemotherapy are associated with improved outcomes over surgery and
chemotherapy in the management of limited-stage small cell esophageal
carcinoma. Radiother Oncol 2013; 106: 317-322. (IF: 5.58)
5. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM. Transcatheter
arterial chemoembolization in combination with radiotherapy for unresectable
hepatocellular carcinoma. Radiother Oncol 2009; 92: 184-194. (IF: 5.58)
6. Meng MB, Wang HH, Guo WH, Zaorsky NG, Shi HS, Zhao LJ, Yuan ZY, Wang
P. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell
lung cancer cell in vitro and in vivo. Cancer Letters 2015; 356: 985-993. (IF:
5.016)

5. 7. Meng M, Wang H, Zaorsky N, Qian D, Zhao L, Yuan Z, Wang P. Multimodality
therapy is recommended for limited-stage combined small-cell esophageal
carcinoma. Int J Radiat Oncol Biol Phys 2014; 90 (Supp): S341 (IF: 4.1)
8. Meng MB, Zaorsky NG, Deng L, Wang HH, Jiang C, Zhao LJ, Yuan ZY, Wang P.
Pericytes: a double-edged sword in cancer therapy. Future Oncol 2014; 2015; 11:
169-179. (IF: 2.6)
9. Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J,
Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation
radiotherapy for locally advanced esophageal squamous cell carcinoma. Thoracic
Cancer 2013; 4: 174-185.
10. Meng MB, Cui YL, Guan YS, Zhang Y, Zheng MH, Yuan CK, Zhang RM.
Traditional Chinese medicine plus transcatheter arterial chemoembolization for
unresectable hepatocellular carcinoma. J Altern Complement Med 2008; 14:
1027-1042
11. Meng MB, Wen QL, Cui YL, She B, Zhang RM. Traditional Chinese medicine
for improving immune response in patients with unresectable hepatocellular
carcinoma after transcatheter arterial chemoembolization. Explore (NY) 2011; 7:
37-43.
12. Guo WH, Meng MB (Co-first author), You X, Luo Y, Li J, Qiu M, Liao ZY.
CT-guided percutaneous vertebroplasty of the upper cervical spine via a
translateral approach. Pain Physician 2012; 15: 733-741.
13. Wen QL, Meng MB (Co-first author), Yang B, Tu LL, Jia L, Zhou L, Xu Y, Lu Y.
Endostar, a recombined humanized endostatin, enhances the radioresponse for
human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in
mice. Cancer Sci 2009; 100: 1510-1519.
14. Yuan ZY, Meng MB (Co-Corresponding author), Liu CL, Wang HH, Jiang C,
Song YC, Zhuang HQ, Yang D, Wang JS, Wei W, Li FT, Zhao LJ, Wang P.
Stereotactic body radiation therapy using CyberKnife system for patients with
liver metastases. Onco Targets Ther 2014; 7: 915-923.
15. Wang HH, Zaorsky NG, Meng MB (Co-Corresponding author), Wu ZQ, Zeng
XL, Jiang B, Jiang C, Zhao LJ, Yuan ZY, Wang P. Multimodality therapy is
recommended for limited-stage combined small-cell esophageal carcinoma. Onco
Targets Ther 2015; 8: 437-444.

6. 16. Zhao M, Meng MB (Corresponding author). Merkel cell carcinoma with lymph
node metastasis in the absence of a primary site: case report and literature review.
Oncol Letters, 2012; 4: 1329-1334.
17. Wang H, Meng M, Jiang C, Qian D, Zhao L, Yuan Z, Wang P. Feasibility and
Efficacy of Stereotactic Body Radiation Therapy Using Robotic Radiosurgery as
Curative Treatment for Metastatic Thyroid Carcinoma. Int J Radiat Oncol Biol
Phys 2014; 90 (Supp): S900
18. Qian D, Yuan Z, Zhang B, Meng M, Zhuang H. Human Positive Cofactor 4 (PC4)
Is a Promising Target to Improve the Radiation Therapy Effect of Esophageal
Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys 2014; 90 (Supp): S803.
19. Deng L, Na FF, Wang JW, Meng MB, He HY, Yang JJ, Jian YS, Wu JJ, Ding J,
Xie D, Liu Y, Mu XM, Li YF, Chen Y, Lu Y. Insufficient screening knowledge in
Chinese interns: a survey in ten leading medical school. Asian Pac J Cancer Prev
2011; 12: 2801-2806.
20. Ji K, Zhao L, Yang C, Meng M, Wang P. Three-dimensional conformal radiation
for esophageal squamous cell carcinoma with involved-infield irradiation may
deliver considerable doses of incidental nodal irradiation. Radiat Oncol, 2012; 7:
200.
21. Mao Q, Zhang Y, Fu X, Xue J, Guo W, Meng M, Zhou Z, Mo X, Lu Y. A tumor
hypoxic niche protect human colon cancer stem cells from chemotherapy. J
Cancer Res Clin Oncol 2013; 139: 211-222.
22. Feng ZX, Zhao LJ, Guan Y, Sun Y, Meng MB, Ji K, Wang P. Identification of
risk factors and characteristics of supraclavicular lymph node metastasis in
patients with small cell lung cancer. Med Oncol 2013; 30: 493.
23. Lan J, Wan XL, Deng L, Xue JX, Wang LS, Meng MB, Ling H, Zhang X, Mo
XM, Lu Y. Ablative hypofractionated radiotherapy normalizes tumor vasculature
in Lewis lung carcinoma mice model. Radiat Res 2013, 179:458-464.
24. Qian D, Zhang B, Zeng XL, Le Blanc JM, Guo YH, Xue C, Jiang C, Wang HH,
Zhao TS, Meng MB, Zhao LJ, Hao JH, Wang P, Xie D, Lu B, Yuan ZY.
Inhibition of human positive cofactor 4 radiosensitizes human esophageal
squmaous cell carcinoma cells by suppressing XLF-mediated nonhomologous
end joining. Cell Death Dis 2014; 5: e1461.

7. 25. Chen T, Zhang Y, Guo WH, Meng MB, Mo XM, Lu Y. Effects of
heterochromatin in colorectal cancer stem cells on radiosensitivity. Chin J Cancer
2010; 29: 270-276.
26. Zhou Q, Zou BW, Xu Y, Xue JX, Meng MB, Liu FJ, Deng L, Ma DY, Ao R, Lu Y.
DNA repair gene polymorphisms and clinical outcome of patients with primary
small cell carcinoma of the esophagus. Tumor Biol 2015; 36: 1539-1548.